NicOx, Merck extend research collaboration, broaden scope

By Angela McDaniels

Seattle, Nov. 2 - NicOx SA announced the extension of its 2003 research collaboration agreement with Merck & Co. Inc. to jointly evaluate selected NicOx nitric oxide-donating compounds.

While the research was initially focused on one class of compounds, NicOx said the two companies have agreed to broaden the field of investigation. Pre-clinical studies will be initiated to identify potential lead candidates for development.

Merck exercised its option to negotiate for a license, development and commercialization agreement during the second quarter of 2005 and will make a payment to NicOx in connection with the extension, NicOx said.

"The conclusion of any future licensing agreement is of course dependent on successful results from the new research program and the agreement of contractual terms. NicOx and Merck expect to conclude this process during 2006," said Michele Garufi, NicOx chairman and chief executive officer.

NicOx is pharmaceutical company headquartered in Sophia-Antipolis, France, that develops nitric oxide-donated drugs for the treatment of inflammation, pain and cardiovascular diseases.

Pharmaceutical company Merck is based in Whitehouse Station, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.